Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $730.00 by Analysts at Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target decreased by Morgan Stanley from $788.00 to $730.00 in a research report report published on Wednesday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock.

REGN has been the topic of a number of other reports. Barclays cut their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Royal Bank Of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a report on Tuesday. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $787.71.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $662.88 on Wednesday. The firm has a fifty day moving average of $647.01 and a two-hundred day moving average of $723.51. The firm has a market cap of $70.08 billion, a P/E ratio of 16.15, a P/E/G ratio of 1.49 and a beta of 0.24. Regeneron Pharmaceuticals has a 1-year low of $541.00 and a 1-year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the previous year, the business earned $8.22 EPS. The business’s quarterly revenue was up 19.0% on a year-over-year basis. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 37.4 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Atwood & Palmer Inc. grew its holdings in Regeneron Pharmaceuticals by 1.5% during the second quarter. Atwood & Palmer Inc. now owns 42,332 shares of the biopharmaceutical company’s stock valued at $26,396,000 after purchasing an additional 630 shares during the last quarter. Palouse Capital Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 6.2% in the second quarter. Palouse Capital Management Inc. now owns 2,479 shares of the biopharmaceutical company’s stock worth $1,546,000 after buying an additional 145 shares during the last quarter. Czech National Bank boosted its holdings in shares of Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. Czech National Bank now owns 28,442 shares of the biopharmaceutical company’s stock worth $17,735,000 after buying an additional 989 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab grew its stake in Regeneron Pharmaceuticals by 17.6% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 24,190 shares of the biopharmaceutical company’s stock valued at $15,083,000 after buying an additional 3,619 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Regeneron Pharmaceuticals by 17.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 244,927 shares of the biopharmaceutical company’s stock valued at $152,722,000 after buying an additional 37,139 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Benchmark upgraded Regeneron Pharmaceuticals to buy from hold, indicating improved confidence in the stock’s outlook and valuation. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Benchmark
• Positive Sentiment: Several analysts still see upside in REGN despite trimming price targets, including Truist and other firms that maintained bullish ratings, suggesting Wall Street remains constructive on the company’s fundamentals. Regeneron price target changes
• Positive Sentiment: Zacks highlighted Regeneron as a strong value stock with a solid earnings surprise history, which may help support sentiment ahead of its next results. Here's Why Regeneron (REGN) is a Strong Value Stock
• Neutral Sentiment: Royal Bank of Canada cut its price target to $696 and kept a sector perform rating, signaling a more cautious but not outright bearish view. Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada
• Neutral Sentiment: Broader biotech optimism, including comments that the sector could become “the hottest group in the market,” may provide some support, though this was not specific to Regeneron. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Negative Sentiment: Director Arthur F. Ryan sold 200 shares in a pre-arranged Rule 10b5-1 transaction, which can weigh on sentiment even though the sale was small. SEC filing for director sale
• Negative Sentiment: Morgan Stanley also lowered its price target on Regeneron, adding to the sense that analysts are tempering near-term expectations for the stock. Morgan Stanley price target cut

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.